PR Newswire·Oct 26, 2026, 8:45 AM ET

Azitra, Inc. Announces Revitalizing Results from Ex Vivo Study of ATR-COSF Demonstrating Ability to Reduce Fine Lines and Improve Elasticity in Human Skin

ATR-COSF is a cosmetic product candidate using a supernatant formulation containing an active recombinant human filaggrin domain in a hydrogel.
Ex vivo testing on two cosmetic surgery skin models showed visible improvements in fine lines, wrinkles, & elasticity after a single dose.
In Model 1 (dorsal skin), ATR-COSF reduced wrinkle appearance by ~15% at 3 hours, ~20% at 24 hours, & ~50% at 48 hours.
Model 1 results indicated ATR-COSF preserved net skin elasticity over 48 hours, whereas the hydrogel vehicle alone caused a decline in elasticity.
In Model 2 (face lift), the 4% ATR-COSF concentration demonstrated superior elasticity improvements compared to the 2% formulation & vehicle control at the 6-hour mark.
A first-in-human clinical study for 4% ATR-COSF involving approximately 30 subjects is anticipated to begin soon with initial data expected by year end 2026.
Azitra, Inc. will present detailed ATR-COSF progress in a live presentation at the BIO-Europe conference in Cologne, Germany on November 10, 2026.
CEO Francisco Salva stated the company remains appropriately funded to reach the clinical data milestone, which may offer investors a near-term opportunity to invest $5.25 million to $10.5 million.